Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
B-cell Non-Hodgkin Lymphoma (B-NHL): early-phase trial registry
2 of 4 indexed B-cell Non-Hodgkin Lymphoma (B-NHL) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 2 currently recruiting · #4,115 of 28,707 conditions by registered trial count
B-cell Non-Hodgkin Lymphoma (B-NHL): 4 US clinical trials tracked, 2 recruiting.
B-cell Non-Hodgkin Lymphoma (B-NHL) is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Cellectis S.A., running 1 of these trials.
Enrollment posture brief
Registry condition b-cell-non-hodgkin-lymphoma-b-nhl
OPEN 2 | RECR 50% | LATE 0 | EARLY 4 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
B-cell Non-Hodgkin Lymphoma (B-NHL) lists 2 open slots (50% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for B-cell Non-Hodgkin Lymphoma (B-NHL) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
B-cell Non-Hodgkin Lymphoma (B-NHL) is recruiting above its size-band peers.
2 of 4 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
Cellectis S.A.
NCT05607420
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
University of Colorado, Denver
NCT05098613
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
Regeneron Pharmaceuticals
NCT03888105
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
Novartis Pharmaceuticals
NCT05397496
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on B-cell Non-Hodgkin Lymphoma (B-NHL) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on B-cell Non-Hodgkin Lymphoma (B-NHL) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this B-cell Non-Hodgkin Lymphoma (B-NHL) page
4 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 B-cell Non-Hodgkin Lymphoma (B-NHL) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Cellectis S.A. sponsors the most B-cell Non-Hodgkin Lymphoma (B-NHL) trials on record, review their full trial history before evaluating a specific study. See Cellectis S.A.'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This B-cell Non-Hodgkin Lymphoma (B-NHL) condition card totals 4 registered trials; most-linked intervention PIT565; top US site state Illinois. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.